Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRd followed by ciltacabtagene autoleucel versus VRd followed by lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
2023-505850-16-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Planned start Aug 2021; status: authorised.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-505850-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505850-16-00.